Central components of the analgesic/antihyperalgesic effect of nimesulide: Studies in animal models of pain and hyperalgesia

Drugs

Volumn 63, Issue SUPPL. 1, 2003, Pages 9-22

  Tassorelli, Cristina ^a   Greco, Rosaria ^a   Sandrini, Giorgio ^a   Nappi, Giuseppe ^a,b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FORMALDEHYDE; GLYCERYL TRINITRATE; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTEIN FOS; TUMOR NECROSIS FACTOR ALPHA;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HYPERALGESIA; IMMUNOCYTOCHEMISTRY; LOCUS CERULEUS; MALE; NOCICEPTION; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; RAT; SOLITARY TRACT NUCLEUS; SUPRAOPTIC NUCLEUS; TAIL FLICK TEST;

ANIMALIA;

EID: 0038045721     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363001-00003     Document Type: Conference Paper

References (70)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5
2. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299-332.
3. Taiwo YO, Levine JD. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 1998; 8: 1346-9
4. 2 to conscious mice. Brain Res 1990; 510: 26-32
5. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276-9
6. 2. Br J Pharmacol 1994; 112: 735-40
7. 2. Pain 1994; 57: 217-23
8. Vanegas H, Schaible H-G. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol 2001; 64: 327-63
9. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164
10. Kawabata A, Umeda N, Takagi H. L-Arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway. Br J Pharmacol 1993; 109: 73-9
11. Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993; 54: 291-300
12. Wiertelak EP, Furness LE, Watkins LR, et al. Illness-induced hyperalgesia is mediated by a spinal NMDA-nitric oxide cascade. Brain Res 1994; 664: 9-16
13. Linden DR, Seybold VS. Spinal neurokinin receptors mediate thermal but not mechanical hyperalgesia via nitric oxide. Pain 2000; 80: 309-17
14. Hamalainen MM, Lovick TA. Involvement of nitric oxide and serotonin in modulation of antinociception and pressor response evoked by stimulation in the dorsolateral region of the periaqueductal gray matter in the rat. Neuroscience 1997; 80: 821-7
15. Aley KO, Mc Cater G, Levine JO. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neurosci 1998; 18: 7008-14
16. Gao WC, Ojao JT. Nitric oxide contributes to both spinal nociceptive transmission and its descending inhibition in rats: an immunocytochemical study. Neurosci Lett 1998; 40: 143-6
17. Ferreira J, Santos AR, Calixtom JB. The role of systemic spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice. Neuropharmacology 1999; 38: 835-42
18. Urban MO, Gebhart GF. Supraspinal contribution to hyperalgesia. PNAS 1999; 96: 7687-92
19. Dawson TM, Snyder SH. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 1994; 14: 5137-53
20. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995; 57: 683-706
21. Coderre TJ. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rat. Molec Biol 1993; 7: 229-46
22. Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 1994; 6: 1328-34
23. Kitto KF, Haley JE, Wilcox GL. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci Lett 1992; 148: 1-5
24. Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391: 281-5
25. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9-43
26. Ferreira SH. The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46: 1-9
27. Kaube H, Hoskin HL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33: 541-4
28. Sandrini M, Vitale G, Pini LA. Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology 2002; 65: 193-7
29. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl. 5: 13-23
30. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60
31. Davis R, Brodgen RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431-54
32. Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995; 682: 167-78
33. Tassorelli C, Joseph SA, Buzzi G, et al. The effect on the central nervous system of nitroglycerin - putative mechanisms and mediators. Prog Neurobiol 1999; 57: 606-24
34. Tassorelli C, Joseph SA, Nappi G. Neurochemical mechanisms of nitroglycerin-induced neuronal activation. Neuropharmacology 1997; 10: 1417-24
35. Tassorelli C, Greco R, Morocutti A, et al. Nitric oxide-induced neuronal activation in the central nervous system as an animal model for migraine: mechanisms and mediators. Funct Neurol 2001; 16 Suppl 4: 69-76
36. Jones MG, Lever I, Bingham S, et al. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia 2001; 21: 643-55
37. Reuter U, Chiarugi A, Bolay H, et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507-16
38. Tassorelli C, Greco R, Wang D, et al. Nitroglycerin induces hyperalgesia in rats - a time-course study. Eur J Pharmacol 2003; 464: 159-62
39. D'Armour FE, Smith DC. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1980; 72: 74-9
40. Tjolsen A, Berge OG, Hunskaar S, et al. The formalin test: an evaluation of the method. Pare 1992; 51: 5-17
41. Hao S, Takahata O, Iwasaki H. Intrathecal endorphin-1 produces antinociceptive activities modulated by alpha 2-adrenoceptors in the rat tail flick, tail pressure and formalin tests. Life Sci 2000; 66: 195-204
42. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983; 306: 686-8
43. Sengupta S, Velpandian T, Sapra P, et al. Comparative analgesic efficacy of nimesulide and diclofenac gels after topical application on the skin. Skin Pharmacol Appl Skin Physiol 1998; 11: 273-8
44. Gupta SK, Bansal P, Bhardwaj RK, et al. Comparative antinociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and pipeline combination. Pharmacol Res 2000; 41: 657-62
45. Matsumoto H, Naraba H, Ueno A, et al. Inhibition of cyclooxygenase-2 causes an enhancement of writhing response in mice. Eur J Pharmacol 1998; 352: 47-52
46. Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract 2002; 128 Suppl. 1: 11-9
47. Islas-Cadena M, Banuelos P, Granados-Soto V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide. J Pharmacol Toxicol Metab 1999; 42: 87-92
48. Torfgard K, Ahnler J, Axelsson KL, et al. Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol Toxicol 1989; 64: 369-72
49. Mashimo T, Pak M, Choe H, et al. Effects of vasodilators guanethidine, nicardipine, nitroglycerin, and prostaglandin E1 on primary afferent nociceptors in humans. J Clin Pharmacol 1997; 37: 330-5
50. Sandrini G, Tassorelli C, Proietti Cecchini A, et al. Effects of nimesulide on nitric oxide-induced hyperalgesia in humans - a neurophysiological study. Eur J Pharmacol 2002; 450: 259-62
51. Taniguchi Y, Yokoyama K, Inui K, et al. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 1997; 330: 221-9
52. Taniguchi Y, Ikesue A, Yokoyama K, et al. Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, of prostaglandin endoperoxidase synthase-2 activity in vitro. Pharmacol Sci 1995; 1: 173-5
53. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittelforschung 1995; 45: 1096-8
54. Beiche F, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1988; 47: 482-7
55. Maihofner C, Tegeder I, Euchenhofer C, et al. Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord. Neuroscience 2000; 101: 1093-108
56. 2 release in the spinal cord. J Neurochem 2001; 79: 777-86
57. Torres-Lopez JE, Ortiz M, Castaneda-Hernandez G, et al. Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 2002; 70: 1669-76
58. Euchenhofer C, Maihofner C, Brune K, et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 1998; 248: 25-8
59. Mazario J, Gaitan G, Herrero JF. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neurpharmacology 2001; 40: 937-46
60. 2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21: 5847-53
61. Yamamoto T, Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg 2002; 94: 962-7
62. Coderre TJ, Katz J, Vaccarino AL, et al. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259-85
63. Sasaki M, Tohda C, Kuraishi Y. Region-specific increase in glutamate release from dorsal horn of rats with adjuvant inflammation. Neuroreport 19981; 9: 3219-22
64. Sluka KA, Willis WD. Increased spinal release of excitatory amino acids following intradermal injection of capsaicin is reduced by a protein kinase G inhibitor. Brain Res 1998; 798: 281-6
65. DeGroot J, Zhow S, Carlton SM. Peripheral glutamate release in the hind paw following low and high intensity sciatic stimulation. Neuroreport 2000; 14: 497-502
66. Lawand NB, McNearney T, Westlund KN. Amino acid release into the knee joint: key role in nociception and inflammation. Pain 2000; 86: 69-74
67. 2 causes sensitization of the primary afferent neuron via the spinal release of glutamate. Inflamm Res 1996; 45: 499-502
68. Kawamata T, Omote K. Activation of spinal N-methyl-D-aspartate receptor stimulates a nitric oxide/cyclic guanosine 3,5-monophosphate/glutamate release cascade in nociceptive signaling. Anesthesiology 1999; 91: 1415-24
69. Dickenson AH. A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990; 11: 307-9
70. 2 alpha injected into conscious mice. Pain 1994; 57: 225-31